Protective antitumor immunity induced by immunization with completely allogeneic tumor cells

Cancer Research

Volumn 56, Issue 16, 1996, Pages 3782-3787

  Toes, René E M ^a   Blom, Ria J J ^a   Van Der Voort, Ellen ^a   Offringa, Rienk ^a   Melief, Cornelis J M ^a   Kast, W M ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR CELL VACCINE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER IMMUNIZATION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EMBRYO; FLUORESCENCE ACTIVATED CELL SORTER; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANIMALS; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0029783148     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Greenberg, P. D. Adoptive T-cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol., 49: 281-355, 1991
2. Melief, C. J. M Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res., 58: 143-175, 1992.
3. Yewdell, J. W., and Bennink, J. R. The binary logic of antigen processing and presentation to T cells. Cell, 62: 203-206, 1990.
4. Momburg, F., Neefjes, J. J., and Hämmerling, G. J. Peptide selection by MHC-encoded TAP transporters. Curr. Opin. Immunol., 6: 32-37, 1994.
5. Bevan, M. J. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med., 143: 1283-1288, 1976
6. Gooding, L. R., and Edwards, C. B H-2 antigen requirements in the in vitro induction of SV-40-specific cytotoxic T lymphocytes J. Immunol., 124: 1258-1262, 1980.
7. Huang, A Y. C , Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (Washington DC), 264: 961-965, 1994
8. Bevan, M. J. Antigen presentation to cytotoxic T lymphocytes. J. Exp. Med , 182: 639-641, 1995.
9. Kundig, T M., Bachman, M. F., Dipaolo, C., Simard, J. J. L , Battegay, M., Lother, H, Gessner, A , Kuhlcke, K., Ohashi, P S , Hengartner, H., and Zinkernagel, R. M Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science (Washington DC), 268: 1343-1347, 1995
10. Hoover, H C, Surdyke, M. G , Dangel, R B , Peters, L C., and Hanna, M. G. Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer (Phila.), 55: 1236-1243, 1985.
11. Berd, D., Maguire, H. C., McCue, P., and Mastrangelo, M. J. Treatment of metastatic melanoma with an autologous tumor cell vaccine: clinical and immunologic results in 64 patients. J. Clin Oncol., 8: 1858-1867, 1990
12. McCune, C. S., O'Donnel, R. W., Marquis, D. M., and Sahasrabudhe, D M. Renal cell carcinoma treated by vaccines for active- specific immunotherapy: correlation of survival with skin testing by autologous tumor cells. Cancer Immunol. Immunother., 32: 62-66, 1990.
13. Mitchell, M. S., Harel, W , Kempf, R. A , Hu, E , Kan-Mitchell, J., Boswell, W. D., Dean, G , and Stevenson, L. Active-specific immunotherapy for melanoma. J Clin. Oncol, 8: 856-869, 1990
14. Pardoll, D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev. Immunol, 13: 399-415, 1995.
15. Schendel, D J , Gansbacher, B., Oberneder, R., Kriegmair, M., Hofstetter, A., Riethmuller, G., and Segurado, O. G. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. J. Immunol., 151: 4209-4220, 1993.
16. van Pel, A., van der Bruggen, P., Coulie, P. G , Brichard, V. G , Lethé, B., van den Eynde, B., Uyttenhove, C., Renauld, J-C., and Boon, T. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev., 145: 229-250, 1995.
17. Kast, W M , Offringa, R., Peters, P. J., Voordouw, A. C , Meloen, R. H., Van der Eb, A. J , and Melief, C. J. M. Eradication of adenovirus El-induced tumors by Ela-specific cytotoxic T lymphocytes. Cell, 59: 603-615, 1989.
18. Toes, R. E. M., Offringa, R , Blom, H. J. J., Brandt, R. M. P., Van der Eb, A. J., Melief, C J. M., and Kast, W M. An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. J. Immunol., 154: 3396-3405, 1995.
19. Toes, R. E. M , Blom, R. J J., Offringa, R., Kast, W. M , and Melief, C J. M. Functional deletion of tumor-specific cytotoxic T lymphocytes induced by peptide immunization can lead to the inability to reject tumors J Immunol., 156, 3911-3918, 1996.
20. Feltkamp, M. C. W., Smits, H. L., Vierboom, M P. M., Minnaar, R. P., De Jongh, B. M., Drijfhout, J. W., Ter Schegget, J , Melief, C. J. M., and Kast, W. M. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papilloma virus type 16-transformed cells. Eur. J. Immunol., 23: 2242-2249, 1993.
21. th American Peptide Symposium, pp. 1003-1004. Leiden, the Netherlands: ESCOM Science Publishers, 1990
22. b haplotype reveal genetic control of isotype expression. J Immunol., 126: 317-321, 1981.
23. k antibody. In: C. Steinberg and I. Lefkovits (eds.), The Immune System, pp. 202-209. Basel: S. Karger AG, 1981.
24. d antigens on the surface of these cells. Transplantation (Baltimore), 34: 113-120, 1982.
25. Lemke, H., Hämmerling, G. J , and Hämmerling, U. Fine specificity analysis with monoclonal antibodies of antigens controlled by the MHC and by the Qa/TL region in mice. Immunol. Rev., 47: 175-206, 1979.
26. Traversari, C., Van der Bruggen, P., Van den Eynde, B., Hainaut, P., Lemoine, C., Ohta, N , Old, L., and Boon, T. Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous CTL Immunogenetics, 35: 145-152, 1992
27. + T cells to an antigen that no longer serves as a target. J. Exp. Med., 178: 933-940, 1993.
28. Srivastava, P. K., Udono, H., Blachere, N. E , and Li, Z Heat shock proteins transfer peptides during antigen processing and CTL priming Immunogenetics, 39: 93-98, 1994
29. Barth, A., Hoon, D. S. B , Foshag, L. J., Nizze, A., Famatiga, E., Okun, E., and Morton, D. L. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res., 54: 3342-3345, 1994.
30. Rosenthal, F. M., Zier, K. S , and Gansbacher, B Human tumor vaccines and genetic engineering of tumors with cytokine and histocompatibility genes to enhance immunogenicity. Curr Opin Oncol., 6: 611-615, 1994.
31. Boon, T., Cerottini, J-C., van den Eynde, B , van der Bruggen, P., and van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev Immunol., 12: 337-365, 1994.
32. Hui, K., Grosveld, F., and Festenstein, H. Rejection of transplantable AKR leukemia cells following MHC DNA-mediated cell transformation. Nature (Lond.), 311: 750-752, 1984.
33. Hui, K. M., Sim, T F., Foo, T. T., and Oei, A. A. Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene J. Immunol., 143: 3835-3843, 1989.
34. Leach, D. R., and Callahan, G. N. Fibrosarcoma cells expressing allogeneic MHC class II antigens induce protective immunity. J. Immunol., 154: 738-743, 1995.